Selumetinib Shrinks NF1-Plexiform Neurofibromas in Adults, Too

(MedPage Today) — CHICAGO — Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial showed.
After 16 cycles…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115874

Author :

Publish date : 2025-06-03 15:43:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Selumetinib Shrinks NF1-Plexiform Neurofibromas in Adults, Too

All International Travelers Should Get Measles Vaccinations, CDC Says

Discovering the marvels of mucus is inspiring amazing new medicines

Related Posts

Nefecon Shows IgAN Benefits Regardless of Baseline eGFR

Why Choose Second Opinions? Risky Cancer Searches; 18 Months to Live, 20 Years Later

Global Stroke Deaths Still a Concern, and It’s Not Just About Developing Countries

How Trump’s Pick for Surgeon General Uses Her Big Online Following to Make Money

Women find other women’s faces even more attractive than men do

GLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA Warns

Nefecon Shows IgAN Benefits Regardless of Baseline eGFR

Why Choose Second Opinions? Risky Cancer Searches; 18 Months to Live, 20 Years Later

Global Stroke Deaths Still a Concern, and It’s Not Just About Developing Countries

How Trump’s Pick for Surgeon General Uses Her Big Online Following to Make Money

Women find other women’s faces even more attractive than men do

GLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA Warns

Experts Suggest NHS Heart Risk Checks from Age 25

Experimental MS Drug Nearly Eliminates Disease Activity

Categories

Archives